Clinical trial
A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa
NCT02564523 is registered in ClinicalTrials.gov with Janssen Vaccines & Prevention B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 6, 2015
- Completion date
- February 12, 2019
- Enrollment
- 1,075 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.